RHPS has just mentioned the above in an e-mail, they have gone up 240% today - started at 0.60 and finished up at 1.65. Look to be quite interesting.

Time will tell!

Update from their website.

level 2 strong right now http://www.sareum.co.uk/base/images/pdfs/SareumMay20052011.pdf

4.2p fair value

Just sold half at >100%. Should have done so on the last up.

well done - bit early to sell yet - l2 very strong buying but understand why some going too early - gl

could be a 50% + peak

Gibby - I have more than my original stake back and am happy to let the remainder run - a policy I try to adhere to with "tiddlers".

good policy

profit takers about right now

Looks like Sar's running out of steam?

The boilers been stoked!...

Preclinical Development Candidate Selected for Chk1 Inhibitor Programme
Share this article
print


TIDMSAR

(AIM: SAR) 15 August 2011



SAREUM HOLDINGS PLC ("Sareum")

Preclinical Development Candidate Selected for Chk1 Inhibitor Programme

Sareum, the specialist cancer drug discovery business, The Institute of Cancer
Research ("the ICR") and Cancer Research UK's commercial arm, Cancer Research
Technology Limited ("CRT") are pleased to announce the selection of a

preclinical development candidate from their joint research collaboration.

The joint research collaboration targets Chk1 (Checkpoint Kinase 1). Chk1 is
important in controlling a cancer cell's response to DNA damage, which may be a

consequence of the cancer itself, or intentionally caused by chemotherapy or
radiotherapy.

Preclinical model studies carried out at the Cancer Research UK Cancer
Therapeutics Unit at the ICR demonstrate that the Chk1 candidate, dosed via the

oral route, in combination with the chemotherapeutics gemcitabine or irinotecan
significantly reduces cancer growth rates compared to treatment with the same

dose of chemotherapeutic without the Chk1 inhibitor.

Further preclinical studies demonstrate the potential for the collaboration Chk1
development candidate to reduce tumour growth when given as a sole treatment in

models of certain cancer types that are believed to be dependent on Chk1 for
survival.

Sareum's CEO, Dr Tim Mitchell, commented: "The selection of a preclinical
development candidate is a major milestone for the collaboration that will

significantly enhance the licensing package. Our research indicates that the
selectivity and oral dosing properties of this candidate give it a competitive
advantage."

Professor Paul Workman, Director of the Cancer Research UK Cancer Therapeutics

Unit at the ICR, said: "The significant progress made so far is very pleasing
and highlights the value of partnerships between industry and academic drug

discovery groups like ours. There is further important development work to be
done so that patients can one day benefit from these drugs, and we look forward
to the progress of the compound towards the clinic."


Dr Philip Masterson, Associate Director at Cancer Research Technology, said: "We
are working to select the right commercial partner to take the Chk1 programme
into clinical development. Our ultimate aim is that one day, this drug will

become available to treat a range of cancers and save more lives from the

disease.

Our scientists have shown that this drug is promising in preclinical studies,
and we hope further research will prove that it can be used on its own or
alongside chemotherapy and radiotherapy to destroy cancer cells in patients."


For Further Information:

Sareum Holdings pl

No 1 on the LSE top listhot enough?

Certainly a step in the right direction Tabby. "One small step.........." etc!

Sareum Holdings plc

("Sareum" or "the Company")

Final Results

Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery business,
is pleased to announce its final results for the year ended 30 June 2011.

Operational Highlights
* Significant progress on the two most advanced cancer programmes including
positive in-vivo efficacy data from Chk1 and Aurora+FLT3 programmes
* Nomination of preclinical development candidate for Chk1 in August 2011

Financial Highlights
* GBP950,000 (before expenses) raised by way of three share placings
* Cash at bank and in hand of GBP871,000; sufficient cash resources for
foreseeable future, based on current spending levels
* Loss on ordinary activities (after taxation) GBP568,000 (2010: GBP569,000 loss)
in line with expectations

Tim Mitchell, Chief Executive Officer of the Company, said: "The announcement of
two successful in-vivo efficacy studies, and the selection of a preclinical
development candidate, bring Sareum closer to the commercialisation of drug
candidates from our in-house development pipeline. We are currently actively
seeking to license these programmes in order to allow us to drive forward other
programmes that have been generated from our SKIL platform.

The placings during the course of the year, which raised a total of GBP950,000,
have provided us with sufficient working capital for the foreseeable future to
continue the current level of development of our in-house programmes."

Thanks SkinnyThere are four statements by SAR that convince me this investment is sound :-

Significant progress on the two most advanced cancer programmes including positive in-vivo efficacy data from Chk1 and Aurora+FLT3

Sufficient cash resources for foreseeable future

Two successful in-vivo efficacy studies, and the selection of a preclinical
development candidate

We are now actively engaged in talks over potential licensing and co-development agreements with interested parties.

With the present state of market confidenceI would suggest this a great stock pick!

well no bad news really but only problem with pharmas is they can take an age to get anywhere due to the nature of their business - looks good for the future perhaps

Good news from Sar, hopefully more to come... Certainly seems like it!

On the move up again.
News coming??

Have not posted on MoneyAm for ages. This is the first share I have bought to hold in 10 years. Have been buying SAR since May 2011.

Anyone else currently in SAR?

@Howard0181 yes there certainly was a lot of movement around that time.

Shareprice has been very quiet, needs another RNS to liven it up I think..

Good luck Howard!

Rns out tomorrow, expecting good things for SAR!